Market Research Logo

Guardant Health Inc (GH) - Product Pipeline Analysis, 2019 Update

Summary

Guardant Health Inc (Guardant Health) is a precision oncology company that commercializes novel therapeutics for cancer. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Guardant Health Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company


Guardant Health Inc Company Overview
Guardant Health Inc Company Snapshot
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc – Pipeline Analysis Overview
Guardant Health Inc - Key Facts
Guardant Health Inc - Major Products and Services
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Pipeline Products Overview
Anti-RSP03 Antibody Based Blood Test
Anti-RSP03 Antibody Based Blood Test Product Overview
Gene-Based Test - Lung Cancer
Gene-Based Test - Lung Cancer Product Overview
Gene-Based Test - Lung Cancer Clinical Trial
GUARDANT360
GUARDANT360 Product Overview
GUARDANT360 Clinical Trial
Guardant360 CDx Test - Tagrisso
Guardant360 CDx Test - Tagrisso Product Overview
Guardant360 CDx Test - Tepotinib
Guardant360 CDx Test - Tepotinib Product Overview
Guardant360 Companion Diagnostic Assay - Glesatinib
Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview
GuardantOMNI Test - Imfinzi
GuardantOMNI Test - Imfinzi Product Overview
GuardantOMNI Test - Imfinzi Clinical Trial
LUNAR Assay
LUNAR Assay Product Overview
Guardant Health Inc - Key Competitors
Guardant Health Inc - Key Employees
Guardant Health Inc - Locations And Subsidiaries
Head Office
Recent Developments
Guardant Health Inc, Recent Developments
May 15, 2019: Guardant Health to present Precision Oncology data across the continuum of care at the ASCO Annual Meeting
May 09, 2019: Guardant Health reports first quarter 2019 financial results and raises 2019 revenue guidance
Apr 23, 2019: Guardant Health names Dr. Bahija Jallal to its Board of Directors
Apr 15, 2019: NILE study results demonstrating Guardant360’s high concordance to tissue testing in advanced NSCLC published in Clinical Cancer Research
Apr 09, 2019: Guardant Health announces commercial payer progress with more than 150 Million lives covered for Guardant360
Apr 01, 2019: Resolution Liquid Biopsy Assay outperforms Guardant360 in retrospective non-small cell lung carcinoma comparison pilot study
Mar 28, 2019: Palmetto issues draft local coverage determination expanding Guardant360 medicare coverage to most solid tumor types
Mar 27, 2019: Resolution liquid biopsy assay detects more actionable oncogenic fusions with higher allele frequency than Guardant360
Mar 12, 2019: Guardant Health announces fourth quarter and full year 2018 financial results
Feb 28, 2019: Study finds Guardant blood test as effective as tissue biopsy
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Indication
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc, Key Facts
Guardant Health Inc, Major Products and Services
Guardant Health Inc Number of Pipeline Products by Development Stage
Guardant Health Inc Pipeline Products Summary by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status
Guardant Health Inc Ongoing Clinical Trials Summary
Anti-RSP03 Antibody Based Blood Test - Product Status
Anti-RSP03 Antibody Based Blood Test - Product Description
Gene-Based Test - Lung Cancer - Product Status
Gene-Based Test - Lung Cancer - Product Description
Gene-Based Test - Lung Cancer - Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer
GUARDANT360 - Product Status
GUARDANT360 - Product Description
GUARDANT360 - A Phase I Trial of Vemurafenib in Combination with Cetuximab and Irinotecan in Patients with BRAF V600 Mutant Advanced Solid Malignancies
GUARDANT360 - An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection
GUARDANT360 - Next Generation Personalized tX(Therapy) with Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
GUARDANT360 - Noninvasive versus Invasive Lung Evaluation
GUARDANT360 - Open-label, Phase II Study of Trastuzumab in Combination with Lapatinib (Cohort A) or Pertuzumab in Combination with Trastuzumab-emtansine (Cohort B) in Patients with HER2-positive Metastatic Colorectal Cancer: The HERACLES (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification)Trial
Guardant360 CDx Test - Tagrisso - Product Status
Guardant360 CDx Test - Tagrisso - Product Description
Guardant360 CDx Test - Tepotinib - Product Status
Guardant360 CDx Test - Tepotinib - Product Description
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Status
Guardant360 Companion Diagnostic Assay - Glesatinib - Product Description
GuardantOMNI Test - Imfinzi - Product Status
GuardantOMNI Test - Imfinzi - Product Description
GuardantOMNI Test - Imfinzi - A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-based Chemotherapy in First Line Treatment of Patients with Advanced or Metastatic Non Small-cell Lung Cancer (NSCLC) (MYSTIC)
LUNAR Assay - Product Status
LUNAR Assay - Product Description
Guardant Health Inc, Key Employees
Glossary
List of Figures
Guardant Health Inc Pipeline Products by Equipment Type
Guardant Health Inc Pipeline Products by Development Stage
Guardant Health Inc Ongoing Clinical Trials by Trial Status

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report